{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:09:55Z","timestamp":1790168995910,"version":"4.1.0"},"reference-count":131,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Aptamers or chemical antibodies are single-stranded DNA or RNA oligonucleotides that bind proteins and small molecules with high affinity and specificity by recognizing tertiary or quaternary structures as antibodies. Aptamers can be easily produced in vitro through a process known as systemic evolution of ligands by exponential enrichment (SELEX) or a cell-based SELEX procedure. Aptamers and modified aptamers, such as slow, off-rate, modified aptamers (SOMAmers), can bind to target molecules with less polar and more hydrophobic interactions showing slower dissociation rates, higher stability, and resistance to nuclease degradation. Aptamers and SOMAmers are largely employed for multiplex high-throughput proteomics analysis with high reproducibility and reliability, for tumor cell detection by flow cytometry or microscopy for research and clinical purposes. In addition, aptamers are increasingly used for novel drug delivery systems specifically targeting tumor cells, and as new anticancer molecules. In this review, we summarize current preclinical and clinical applications of aptamers in malignant and non-malignant hematological diseases.<\/jats:p>","DOI":"10.3390\/ijms21093252","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T14:00:43Z","timestamp":1588600843000},"page":"3252","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-6848","authenticated-orcid":false,"given":"Valentina","family":"Giudice","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, Baronissi, 84081 Salerno, Italy"},{"name":"Unit of Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mensitieri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, Baronissi, 84081 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-7569","authenticated-orcid":false,"given":"Viviana","family":"Izzo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, Baronissi, 84081 Salerno, Italy"},{"name":"Unit of Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Filippelli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, Baronissi, 84081 Salerno, Italy"},{"name":"Unit of Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, Baronissi, 84081 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"ref_1","unstructured":"Rodgers, G.P., and Young, N.S. (2013). The Bethesda Handbook of Clinical Hematology, Lippincott Williams & Wilkins. [4th ed.]. (In English)."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.critrevonc.2016.08.003","article-title":"Aptamers in hematological malignancies and their potential therapeutic implications","volume":"106","author":"Ouyang","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2011.08807.x","article-title":"Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies","volume":"155","author":"Shigdar","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.omtn.2018.08.023","article-title":"Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies","volume":"13","author":"Yang","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic Antisense Oligonucleotides Are Coming of Age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of microRNAs in vivo with \u2018antagomirs\u2019","volume":"438","author":"Rajewsky","year":"2005","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9528","DOI":"10.1093\/nar\/gkx632","article-title":"Antisense oligonucleotides targeting translation inhibitory elements in 5\u2032 UTRs can selectively increase protein levels","volume":"45","author":"Liang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular Mechanisms of Antisense Oligonucleotides","volume":"27","author":"Stanley","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1101\/gad.13.24.3191","article-title":"Targeted mRNA degradation by double-stranded RNA in vitro","volume":"13","author":"Tuschl","year":"1999","journal-title":"Genes Dev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S2352-3026(18)30021-8","article-title":"Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: A single-centre; open-label; dose-escalation; phase 1\/1b trial","volume":"5","author":"Ohanian","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1517\/14728222.12.8.1021","article-title":"Grb2 signaling in cell motility and cancer","volume":"12","author":"Giubellino","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/JCO.2016.34.15_suppl.7010","article-title":"Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies","volume":"34","author":"Ohanian","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/108729002760220798","article-title":"Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment","volume":"12","author":"Klasa","year":"2002","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2353\/ajpath.2007.070120","article-title":"Brothers in arms: DNA enzymes; short interfering RNA; and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies","volume":"171","author":"Bhindi","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.drudis.2008.03.014","article-title":"Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?","volume":"13","author":"Rayburn","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","article-title":"5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized; phase III trial of fludarabine plus cyclophosphamide with or without oblimersen","volume":"27","author":"Moore","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1200\/JCO.2009.21.8172","article-title":"Phase I\/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia","volume":"27","author":"Schimmer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clml.2011.03.033","article-title":"Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study","volume":"11","author":"Schimmer","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E.N., Carter, J., Dalby, A.B., Eaton, B.E., and Fitzwater, T. (2010). Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015004"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1038\/mtna.2014.49","article-title":"Nucleic Acid Ligands with Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents","volume":"3","author":"Rohloff","year":"2014","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14248","DOI":"10.1038\/s41598-017-14755-5","article-title":"Assessment of Variability in the SOMAscan Assay","volume":"7","author":"Candia","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1021\/acs.jproteome.9b00320","article-title":"Stability of the Human Plasma Proteome to Pre-analytical Variability as Assessed by an Aptamer-Based Approach","volume":"18","author":"Daniels","year":"2019","journal-title":"J. Proteome Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drudis.2014.09.004","article-title":"Turning mirror-image oligonucleotides into drugs: The evolution of Spiegelmer(\u00ae) therapeutics","volume":"20","author":"Vater","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1093\/nar\/gkz252","article-title":"Highly stable hexitol based XNA aptamers targeting the vascular endothelial growth factor","volume":"47","author":"Eremeeva","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1093\/nar\/gky667","article-title":"In vitro selection of an XNA aptamer capable of small-molecule recognition","volume":"46","author":"Rangel","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1002\/cpch.44","article-title":"Selecting Fully-Modified XNA Aptamers Using Synthetic Genetics","volume":"10","author":"Taylor","year":"2018","journal-title":"Curr. Protoc. Chem. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis; treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e26989","DOI":"10.1002\/pbc.26989","article-title":"Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults","volume":"65","author":"McNeer","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3389\/fonc.2019.00726","article-title":"Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances","volume":"9","author":"Chiaretti","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11838","DOI":"10.1073\/pnas.0602615103","article-title":"Aptamers evolved from live cells as effective molecular probes for cancer study","volume":"103","author":"Shangguan","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1166\/jbn.2016.2302","article-title":"A Smart Detection System Based on Specific Magnetic and Rolling Cycle Amplification Signal-Amplified Dual-Aptamers to Accurately Monitor Minimal Residual Diseases in Patients with T-ALL","volume":"12","author":"Li","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1039\/C8AN02342E","article-title":"A novel label-free terbium(iii)-aptamer based aptasensor for ultrasensitive and highly specific detection of acute lymphoma leukemia cells","volume":"144","author":"Wu","year":"2019","journal-title":"Analyst"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s11671-016-1512-8","article-title":"Aptamer-Functionalized Fluorescent Silica Nanoparticles for Highly Sensitive Detection of Leukemia Cells","volume":"11","author":"Tan","year":"2016","journal-title":"Nanoscale Res. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1039\/C4AN00561A","article-title":"A label-free activatable aptamer probe for colorimetric detection of cancer cells based on binding-triggered in situ catalysis of split DNAzyme","volume":"139","author":"Shi","year":"2014","journal-title":"Analyst"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.bios.2009.11.022","article-title":"Selective collection and detection of leukemia cells on a magnet-quartz crystal microbalance system using aptamer-conjugated magnetic beads","volume":"25","author":"Pan","year":"2010","journal-title":"Biosens. Bioelectron."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1039\/c2lc40411g","article-title":"Specific capture and temperature-mediated release of cells in an aptamer-based microfluidic device","volume":"12","author":"Zhu","year":"2012","journal-title":"Lab Chip"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12011","DOI":"10.1021\/ac402989u","article-title":"Label-free and turn-on aptamer strategy for cancer cells detection based on a DNA-silver nanocluster fluorescence upon recognition-induced hybridization","volume":"85","author":"Yin","year":"2013","journal-title":"Anal. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8889","DOI":"10.1002\/anie.201602702","article-title":"N-Heterocyclic Carbene-Gold(I) Complexes Conjugated to a Leukemia-Specific DNA Aptamer for Targeted Drug Delivery","volume":"55","author":"Niu","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1021\/nn201592s","article-title":"Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy","volume":"5","author":"Luo","year":"2011","journal-title":"ACS Nano"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"23000","DOI":"10.1039\/C9NR07391D","article-title":"Sgc8 aptamer targeted glutathione-responsive nanoassemblies containing Ara-C prodrug for the treatment of acute lymphoblastic leukemia","volume":"11","author":"Fang","year":"2019","journal-title":"Nanoscale"},{"key":"ref_45","first-page":"7170","article-title":"Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways","volume":"60","author":"Mathas","year":"2000","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, Present, and Future of Rituximab-The World\u2019s First Oncology Monoclonal Antibody Therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan; anti-CD20 mAb) in non-Hodgkin\u2019s lymphoma: Implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Haghighi, M., Khanahmad, H., and Palizban, A. (2018). Selection and Characterization of Single-Stranded DNA Aptamers Binding Human B-Cell Surface Protein CD20 by Cell-SELEX. Molecules, 23.","DOI":"10.3390\/molecules23040715"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1038\/s41375-019-0441-9","article-title":"CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia","volume":"33","author":"Radpour","year":"2019","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1182\/bloodadvances.2018026112","article-title":"Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)","volume":"3","author":"Yin","year":"2019","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.bbagen.2016.12.015","article-title":"G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms","volume":"1861","author":"Bates","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_52","first-page":"37475","article-title":"Therapeutic applications of AS1411 aptamer, an update review","volume":"S0141-8130","author":"Bayat","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_53","first-page":"367","article-title":"Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics","volume":"1","author":"Vorhies","year":"2007","journal-title":"Biologics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"22270","DOI":"10.18632\/oncotarget.4207","article-title":"AS1411-conjugated gold nanospheres and their potential for breast cancer therapy","volume":"6","author":"Malik","year":"2015","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.xphs.2016.02.021","article-title":"AS1411 Aptamer-Decorated Biodegradable Polyethylene Glycol-Poly(lactic-co-glycolic acid) Nanopolymersomes for the Targeted Delivery of Gemcitabine to Non-Small Cell Lung Cancer In Vitro","volume":"105","author":"Alibolandi","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1158\/1535-7163.MCT-06-0172","article-title":"Discovery and development of anticancer aptamers","volume":"5","author":"Ireson","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_57","first-page":"648","article-title":"Sialic acids siglec interaction: A unique strategy to circumvent innate immune response by pathogens","volume":"138","author":"Khatua","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3324\/haematol.2011.043786","article-title":"High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation","volume":"96","author":"Raponi","year":"2011","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.bbamem.2010.02.004","article-title":"Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals","volume":"1798","author":"Orava","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/cgt.2016.33","article-title":"Coinhibition of overexpressed genes in acute myeloid leukemia subtype M2 by gold nanoparticles functionalized with five antisense oligonucleotides and one anti-CD33(+)\/CD34(+) aptamer","volume":"23","author":"Zaimy","year":"2016","journal-title":"Cancer Gene. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Foster, B.M., Zaidi, D., Young, T.R., Mobley, M.E., and Kerr, B.A. (2018). CD117\/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance. Biomedicines, 6.","DOI":"10.1101\/256099"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1007\/s13277-014-1899-8","article-title":"Diagnostic value of CD117 in differential diagnosis of acute leukemias","volume":"35","author":"Ahmadi","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.biomaterials.2015.07.025","article-title":"Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia","volume":"67","author":"Zhao","year":"2015","journal-title":"Biomaterials"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2019). CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers (Basel), 11.","DOI":"10.3390\/cancers11091358"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/10717544.2017.1367976","article-title":"Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics","volume":"24","author":"Wu","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kotula, J.W., Sun, J., Li, M., Pratico, E.D., Fereshteh, M.P., Ahrens, D.P., Sullenger, B.A., and Kovacs, J.J. (2014). Targeted disruption of \u03b2-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093441"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis; risk stratification; and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2009-08-207126","article-title":"How I treat CLL up front","volume":"115","author":"Gribben","year":"2010","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s10020-018-0001-1","article-title":"Critical molecular pathways in CLL therapy","volume":"24","author":"Ferrer","year":"2018","journal-title":"Mol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00277-013-1967-y","article-title":"The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia","volume":"93","author":"Brachtl","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood.V97.6.1892","article-title":"CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia","volume":"97","author":"Thunberg","year":"2001","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3109\/10428194.2012.751530","article-title":"Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies","volume":"54","author":"Gunnarsson","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"International CLL-IPI Working Group (2016). An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol., 17, 779\u2013790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","article-title":"The Spiegelmer NOX-A12; a novel CXCL12 inhibitor; interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization","volume":"123","author":"Hoellenriegel","year":"2014","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"O\u2019Hayre, M., Salanga, C.L., Kipps, T.J., Messmer, D., Dorrestein, P.C., and Handel, T.M. (2010). Elucidating the CXCL12\/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011716"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2013-12-542480","article-title":"NOX-A12: Mobilizing CLL away from home","volume":"123","author":"Marasca","year":"2014","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4236\/jct.2013.44099","article-title":"Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma","volume":"4","author":"Shum","year":"2013","journal-title":"J. Cancer Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/clpt.2013.58","article-title":"Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12","volume":"94","author":"Vater","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3324\/haematol.2018.205930","article-title":"Olaptesed pegol (NOX-A12) with bendamustine and rituximab: A phase IIa study in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"104","author":"Steurer","year":"2019","journal-title":"Haematologica"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1046\/j.1432-1033.2003.03713.x","article-title":"Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell line specifically binding to aptameric cytotoxic GT oligomers","volume":"270","author":"Dapas","year":"2003","journal-title":"Eur. J. Biochem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"118895","DOI":"10.1016\/j.ijpharm.2019.118895","article-title":"Effects of eEF1A1 targeting by aptamer\/siRNA in chronic lymphocytic leukaemia cells","volume":"574","author":"Dapas","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijpharm.2016.04.031","article-title":"Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects","volume":"506","author":"Scaggiante","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e2457","DOI":"10.1038\/cddis.2016.185","article-title":"Reed-Sternberg cells in Hodgkin\u2019s lymphoma present features of cellular senescence","volume":"7","author":"Gopas","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis; risk-stratification; and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"14543","DOI":"10.3390\/s131114543","article-title":"Biostable ssDNA aptamers specific for Hodgkin lymphoma","volume":"13","author":"Parekh","year":"2013","journal-title":"Sensors (Basel)"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/labinvest.2009.113","article-title":"Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells","volume":"89","author":"Zhang","year":"2009","journal-title":"Lab Investig."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428194.2015.1064530","article-title":"Genetics of anaplastic large cell lymphoma","volume":"57","author":"Zeng","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"8564","DOI":"10.1200\/jco.2015.33.15_suppl.8564","article-title":"The outcome of ALK positive and ALK negative anaplastic large cell lymphoma (ALCL) following DA-EPOCH","volume":"33","author":"Lai","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1477-3155-9-2","article-title":"A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma","volume":"9","author":"Zhao","year":"2011","journal-title":"J. Nanobiotechnol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1002\/smll.201202694","article-title":"An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells","volume":"9","author":"Zhao","year":"2013","journal-title":"Small"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zhao, N., Zeng, Z., and Zu, Y. (2018). Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy. Small, 14.","DOI":"10.1002\/smll.201702103"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1074\/mcp.M700026-MCP200","article-title":"Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt\u2019s lymphoma cells","volume":"6","author":"Mallikaratchy","year":"2007","journal-title":"Mol. Cell Proteom."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1073\/pnas.0909611107","article-title":"DNA aptamer-micelle as an efficient detection\/delivery vehicle toward cancer cells","volume":"107","author":"Wu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/asia.201000242","article-title":"In vivo fluorescence imaging of tumors using molecular aptamers generated by cell-SELEX","volume":"5","author":"Shi","year":"2010","journal-title":"Chem. Asian J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1039\/c2nr12005d","article-title":"DNase-activatable fluorescence probes visualizing the degradation of exogenous DNA in living cells","volume":"4","author":"Gong","year":"2012","journal-title":"Nanoscale"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","author":"Pasqualucci","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.yexmp.2018.11.008","article-title":"Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications","volume":"106","author":"Pratap","year":"2019","journal-title":"Exp. Mol. Pathol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3960\/jslrt.50.121","article-title":"BAFF-R is expressed on B-cell lymphomas depending on their origin; and is related to proliferation index of nodal diffuse large B-cell lymphomas","volume":"50","author":"Takahata","year":"2010","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00277-015-2490-0","article-title":"Expression of BAFF-R; but not BAFF; is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"94","author":"Wang","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1093\/nar\/gkt125","article-title":"Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells","volume":"41","author":"Zhou","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Saltarella, I., Desantis, V., Melaccio, A., Solimando, A.G., Lamanuzzi, A., Ria, R., Storlazzi, C.T., Mariggi\u00f2, M.A., Vacca, A., and Frassanito, M.A. (2020). Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells, 9.","DOI":"10.3390\/cells9010167"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Handa, H., Murakami, Y., Ishihara, R., Kimura-Masuda, K., and Masuda, Y. (2019). The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma. Cancers (Basel), 11.","DOI":"10.3390\/cancers11111738"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.25117","article-title":"Multiple myeloma: 2018 update on diagnosis; risk-stratification; and management","volume":"93","author":"Rajkumar","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3324\/haematol.2013.083592","article-title":"Multiple myeloma: So much progress; but so many unsolved questions","volume":"98","author":"Moreau","year":"2013","journal-title":"Haematologica"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance","volume":"9","author":"Usmani","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/nprot.2010.66","article-title":"Development of DNA aptamers using Cell-SELEX","volume":"5","author":"Sefah","year":"2010","journal-title":"Nat. Protoc."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/leu.2015.216","article-title":"A unique aptamer-drug conjugate for targeted therapy of multiple myeloma","volume":"30","author":"Wen","year":"2016","journal-title":"Leukemia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2012-03-415588","article-title":"Clinical and prognostic role of annexin A2 in multiple myeloma","volume":"120","author":"Seckinger","year":"2012","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.biochi.2018.06.003","article-title":"Screening and characterization of an Annexin A2 binding aptamer that inhibits the proliferation of myeloma cells","volume":"151","author":"Zhou","year":"2018","journal-title":"Biochimie"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1189\/jlb.4RU0615-254RR","article-title":"Cellular and molecular mechanisms in graft-versus-host disease","volume":"99","author":"Zhang","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jcmm.12416","article-title":"Antibody- and aptamer-strategies for GvHD prevention","volume":"19","author":"Oelkrug","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00018-013-1476-0","article-title":"Prevention of graft-versus-host-disease with preserved graft-versus-leukemia-effect by ex vivo and in vivo modulation of CD4(+) T-cells","volume":"71","author":"Fricke","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1172\/JCI69856","article-title":"Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity","volume":"124","author":"Berezhnoy","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra1413485","article-title":"Aplastic Anemia","volume":"379","author":"Young","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"108","author":"Young","year":"2006","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/asheducation-2013.1.76","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"2013","author":"Young","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3324\/haematol.2017.176701","article-title":"Deep sequencing and flow cytometric characterization of expanded effector memory CD8+CD57+ T cells frequently reveals T-cell receptor V\u03b2 oligoclonality and CDR3 homology in acquired aplastic anemia","volume":"103","author":"Giudice","year":"2018","journal-title":"Haematologica"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood-2018-05-844928","article-title":"Macrophage TNF-\u03b1 licenses donor T cells in murine bone marrow failure and can be implicated in human aplastic anemia","volume":"132","author":"Sun","year":"2018","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3324\/haematol.2010.030536","article-title":"Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes","volume":"96","author":"Feng","year":"2011","journal-title":"Haematologica"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.exphem.2018.09.008","article-title":"Aptamer-based proteomics of serum and plasma in acquired aplastic anemia","volume":"68","author":"Giudice","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2010-11-313858","article-title":"Aptamer therapy for SCD?","volume":"117","author":"Anstee","year":"2011","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1089\/nat.2016.0646","article-title":"Identification of Aptamers That Bind to Sickle Hemoglobin and Inhibit Its Polymerization","volume":"27","author":"Purvis","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/nat.2010.0270","article-title":"RNA aptamer therapy for vaso-occlusion in sickle cell disease","volume":"21","author":"Burnette","year":"2011","journal-title":"Nucleic Acid Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2010-05-285718","article-title":"Inhibition of cell adhesion by anti-P-selectin aptamer: A new potential therapeutic agent for sickle cell disease","volume":"117","author":"Gutsaeva","year":"2011","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3252\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:32:36Z","timestamp":1760362356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":131,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["ijms21093252"],"URL":"https:\/\/doi.org\/10.3390\/ijms21093252","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]}}}